ACCESSWIRE
13 May 2022, 22:37 GMT+10
SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. 'Artelo' or the 'Company') (NASDAQ:ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo has been invited to present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually May 16th - 20th, 2022.
Mr. Gorgas is scheduled to present on Monday, May 16, 2022 at 2:00 p.m. ET. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2882/45562. Management will also be available for one-on-one meetings with qualified investors throughout the conference.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.wright@issuerdirect.com.
Investors can register for the conference here.
About the MicroCap Rodeo Spring Into Action Best Ideas Conference
The MicroCap Rodeo is back with its 'Best Ideas Bowl.' This conference is a virtual conference that brings you the top 36 best ideas. Qualified institutional investors recommended each of the 36 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we're focused on alpha.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven pharmaceutical executives collaborating with highly respected researchers and technology experts, Artelo applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to Artelo's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in Artelo's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Artelo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
SOURCE: Artelo Biosciences, Inc.
Get a daily dose of Boston Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Boston Star.
More InformationSYDNEY, NSW, Australia - The euro has jumped above 1.0700 in Asian trading Tuesday, but stocks have fallen sharply.The run ...
MILAN, Italy: Netflix and Italy have agreed to a $59 million settlement to to settle a four-year tax dispute, Milan ...
LONDON, England: British consumers continued to shop as normal last month, despite the highest inflation rate in 40 years, with ...
NEW YORK, New York - U.S. stocks rocketed higher Monday, a rally ignited by a weakening of the U.S. dollar ...
WASHINGTON D.C.: Following baby formula shortages throughout the United States, FDA Commissioner Robert Califf has said that Abbott Laboratories and ...
NEW DELHI, India: Skyroot, India's first privately held company to design, build and test a solid rocket propulsion system, successfully ...
Jayson Tatum recorded 31 points, eight rebounds and five assists as the Boston Celtics dominated from the outset while notching ...
Boston Celtics point guard Marcus Smart will miss Monday night's Game 4 of the Eastern Conference finals against the visiting ...
The Golden State Warriors look to become the first team since Michael Jordan's Chicago Bulls to make six trips to ...
Boston Uprising parted ways Monday with veteran tank Min-seo "Marve1" Hwang over "personal issues." The 21-year-old South Korean joined the ...
After being outscored 32-15 by the New York Yankees while losing three of four during a May 12-15 home series, ...
Miami Heat guard Tyler Herro has been ruled out of Monday night's Game 4 against the Boston Celtics with a ...